AMARIN CORP PLC\UK Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- AMARIN CORP PLC\UK payments for repurchase of common stock for the quarter ending 2016-03-31 was $694.00K, a 493.16% increase year-over-year.
- AMARIN CORP PLC\UK payments for repurchase of common stock for the quarter ending 2015-12-31 was $43.00K.
- AMARIN CORP PLC\UK payments for repurchase of common stock for the quarter ending 2015-09-30 was $34.00K.
- AMARIN CORP PLC\UK payments for repurchase of common stock for the quarter ending 2015-06-30 was $0.00.
- AMARIN CORP PLC\UK payments for repurchase of common stock for fiscal 2015 was $194.00K.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2016-03-31 | $694.00K 10-Q · filed 2016-05-05 | $771.00K derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $194.00K 10-K · filed 2016-02-25 |
| 2015-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | |
| 2015-03-31 | $117.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |